Key Drivers
- Sharp leverage
- Negative cashflow
- Zero revenue
AIAI Summary
Kodiak has shifted into a late‑stage, binary ophthalmology bet where upcoming Phase III readouts (GLOW2, DAYBREAK) and KSI‑101 milestones are the primary drivers of value, compressing upside into near‑term catalysts but concentrating downside risk and forcing likely near‑term financing. Actionable: monitor the P3 results and any non‑dilutive partnership or financing terms—positive readouts plus milestone financing justify adding exposure, while mixed/negative data or dilutive raises at weak prices argue for trimming or avoiding further investment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Sharp leverage
- •Negative cashflow
- •Zero revenue
KOD shows acute deterioration—equity collapsed and debt-to-equity jumped to ~6.9x while zero revenue, sustained negative operating cash flow and heavy R&D spending have strained liquidity despite a market EV that far exceeds book value.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Near support
- •High volatility
Price is trading below its last-month SMA (~$25.22) and sitting at nearby support around $22.0 after a ~20% drop from late‑Feb highs, leaving a near‑term bias toward further weakness unless it reclaims the mid‑$25s or the $27.6–$27.98 resistance cluster.
~20% drop from ~$27.98 (late‑Feb) to $22.25 (mid‑Mar)
Sentiment & News
Key News Insights:
- •Large institutional buying
- •480% stock surge
- •Mixed analyst sentiment
Heavy institutional accumulation—highlighted by Baker Bros.' $53.4M stake and another 386k-share buy—has driven a dramatic stock surge in Kodiak Sciences despite mixed-to-positive analyst ratings on its late-stage ophthalmology pipeline.
Institutional accumulation should keep upward pressure near term, but valuation and divergent analyst views sustain elevated risk for new investors
Similar Companies in Healthcare
Other companies in the same sector with AI ratings